What's GSK's return on marketing?

If you're wondering how GlaxoSmithKline's sales-and-marketing team is doing, we might have the answer. Blogger Jim Edwards looks at GSK's yield on its marketing dollars and finds that they're "just about treading water." The revenue yield and gross profit yield on every dollar the company spent on selling, general, and administrative expenses was flat last quarter, down from 1 percent and 7 percent respectively in the first quarter. "The overall trend seems to be down," Edwards notes. Then he offers some cold comfort: After looking at these numbers for one drugmaker after another, he says, he knows that GSK isn't alone in seeing its marketing ROI lose steam.

- see the post at NRx

Suggested Articles

The cleaning procedures are so poor at a Zydus Cadila plant in India that the FDA says a sampling found 10 different cross-contaminated products.

Oklahoma politicians contend J&J should be on the line for future abatement costs even after a $572 million verdict, but J&J sees things differently.

Abbott helmsman Miles White, who oversaw the spinoffs of AbbVie and Hospira, will step down as CEO after 21 years at the top job.